Our top pick for
Bio-Rad Laboratories, Inc is a medical devices business based in the US. Bio-Rad Laboratories shares (BIO) are listed on the NYSE and all prices are listed in US Dollars. Bio-Rad Laboratories employs 8,000 staff and has a trailing 12-month revenue of around USD$2.3 billion.
|52-week range||USD$309.3801 - USD$573.79|
|50-day moving average||USD$522.0289|
|200-day moving average||USD$482.8651|
|Wall St. target price||USD$603.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$64.502|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Bio-Rad Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Rad Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bio-Rad Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Bio-Rad Laboratories shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Bio-Rad Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.42. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Rad Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bio-Rad Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$409 million.
The EBITDA is a measure of a Bio-Rad Laboratories's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$2.3 billion|
|Operating margin TTM||11.88%|
|Gross profit TTM||USD$1.3 billion|
|Return on assets TTM||1.92%|
|Return on equity TTM||30.33%|
|Market capitalisation||USD$16.3 billion|
TTM: trailing 12 months
There are currently 359,955 Bio-Rad Laboratories shares held short by investors – that's known as Bio-Rad Laboratories's "short interest". This figure is 35.5% down from 557,705 last month.
There are a few different ways that this level of interest in shorting Bio-Rad Laboratories shares can be evaluated.
Bio-Rad Laboratories's "short interest ratio" (SIR) is the quantity of Bio-Rad Laboratories shares currently shorted divided by the average quantity of Bio-Rad Laboratories shares traded daily (recently around 167420.93023256). Bio-Rad Laboratories's SIR currently stands at 2.15. In other words for every 100,000 Bio-Rad Laboratories shares traded daily on the market, roughly 2150 shares are currently held short.
However Bio-Rad Laboratories's short interest can also be evaluated against the total number of Bio-Rad Laboratories shares, or, against the total number of tradable Bio-Rad Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Rad Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bio-Rad Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0168% of the tradable shares (for every 100,000 tradable Bio-Rad Laboratories shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Rad Laboratories.
Find out more about how you can short Bio-Rad Laboratories stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bio-Rad Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 23.57
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bio-Rad Laboratories's overall score of 23.57 (as at 10/01/2020) is pretty good – landing it in it in the 28th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bio-Rad Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 6.03/100
Bio-Rad Laboratories's environmental score of 6.03 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 16.8/100
Bio-Rad Laboratories's social score of 16.8 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.75/100
Bio-Rad Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bio-Rad Laboratories scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bio-Rad Laboratories has, for the most part, managed to keep its nose clean.
|Total ESG score||23.57|
|Total ESG percentile||27.74|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
We're not expecting Bio-Rad Laboratories to pay a dividend over the next 12 months.
Bio-Rad Laboratories's shares were split on a 2:1 basis on 8 March 2002. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Rad Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bio-Rad Laboratories shares which in turn could have impacted Bio-Rad Laboratories's share price.
Over the last 12 months, Bio-Rad Laboratories's shares have ranged in value from as little as $309.3801 up to $573.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bio-Rad Laboratories's is 1.0061. This would suggest that Bio-Rad Laboratories's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.